Article

The preliminary clinical experience with laparoscopic duodenojejunal bypass for treatment of type 2 diabetes mellitus in non-morbidly obese patients: the 1-year result in a single institute.

Department of Surgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 62 Yeouido-dong, Yeongdeungpo-gu, Seoul, 150-713, Korea, .
Surgical Endoscopy (impact factor: 4.01). 06/2012; 26(11):3287-92. DOI:10.1007/s00464-012-2341-1
Source: PubMed

ABSTRACT Although various bariatric surgeries are widely known for their effect of ameliorating type 2 diabetes mellitus (T2DM), there are only a few reports demonstrating the effect of duodenojejunal bypass on T2DM. The aim of this study was to evaluate and report the clinical effects of laparoscopic duodenojejunal bypass (LDJB) in non-morbidly obese patients with T2DM.
Twelve non-morbidly obese patients with T2DM underwent LDJB. Changes in fasting blood glucose, body mass index glycosylated hemoglobin (HbA1c), and dose of antidiabetic medications were recorded prospectively during a 1-year period.
Reduction in HbA1c occurred 3 months after surgery and was maintained up to 1 year, and hyperglycemia was reversed within 1 month after surgery and remained controlled at 12 months. BMI decreased significantly 1 month after surgery and then remained steady through the year. Three patients (25.0 %) stopped antidiabetic medication, seven (58.3 %) patients maintained or decreased doses, and two (16.7 %) increased doses. Seven (58.3 %) patients had a decline in HbA1c.
LDJB demonstrated a glycemic control effect up to 1 year on T2DM in non-morbidly obese patients.

0 0
 · 
0 Bookmarks
 · 
40 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

1 year
 
1-year period
 
12 months
 
3 months
 
ameliorating type 2 diabetes mellitus
 
antidiabetic medication
 
antidiabetic medications
 
body mass index glycosylated hemoglobin
 
clinical effects
 
fasting blood glucose
 
glycemic control effect
 
HbA1c
 
hyperglycemia
 
non-morbidly obese patients
 
prospectively
 
steady
 
T2DM
 
various bariatric surgeries
 

Kwang Yeol Paik